Plasma ceramide concentrations correlate with insulin sensitivity, inflammation and atherosclerotic risk. We hypothesized that plasma ceramide concentrations are increased in the presence of elevated fatty acids and are regulated by increased liver serine palmitoyltransferase (SPT) activity.
Lean humans and rats underwent an acute lipid infusion and plasma ceramide levels were determined. One cohort of lipid infused rats were administered myriocin to inhibit SPT activity. Liver SPT activity was determined in lipid infused rats, and obese, insulin resistant mice. The time and palmitate dose-dependent synthesis of intracellular and secreted ceramide was determined in HepG2 liver cells.
Plasma ceramide levels were increased during lipid infusion in humans and rats, and in obese, insulin resistant mice. The increase in plasma ceramide was not associated with changes in liver SPT activity, and inhibiting SPT activity by ∼50% did not alter plasma ceramide levels in lipid infused rats. In HepG2 liver cells, palmitate incorporation into extracellular ceramide was both dose- and time-dependent, suggesting the liver cells rapidly secreted the newly synthesised ceramide.
Elevated systemic fatty acid availability increased plasma ceramide, but this was not associated with changes in hepatic SPT activity, suggesting that liver ceramide synthesis is driven by substrate availability rather than increased SPT activity. This report also provides evidence that the liver is sensitive to the intracellular ceramide concentration, and an increase in liver ceramide secretion may help protect the liver from the deleterious effects of intracellular ceramide accumulation.